Variable 1* | Variable 2* | All Patients (n = 239) | Placebo Group (n = 120) | GA Group (n = 119) |
---|---|---|---|---|
Pre-study relapses | On-trial relapses | 0.21 (.001) | 0.19 (.04) | 0.25 (.006) |
Pre-study relapses | Baseline EL | 0.10 | 0.09 | 0.11 |
Pre-study relapses | On-trial EL | 0.15 (.02) | 0.14 | 0.20 (.03) |
Pre-study relapses | On-trial new T2 lesions | 0.19 (.003) | 0.15 | 0.27 (.003) |
On-trial relapses | Baseline EL | 0.25 (<.001) | 0.30 (.001) | 0.22 (.02) |
On-trial relapses | On-trial EL | 0.30 (<.001) | 0.36 (<.001) | 0.21 (.02) |
On-trial relapses | On-trial new T2 lesions | 0.32 (<.001) | 0.34 (<.001) | 0.25 (.006) |
Baseline EL | On-trial EL | 0.64 (<.001) | 0.66 (<.001) | 0.65 (<.001) |
On-trial EL | On-trial new T2 lesions | 0.88 (<.001) | 0.90 (<.001) | 0.84 (<.001) |
Note.—Values are the Spearman rank correlation coefficients. Data in parentheses are P values ≤.05.
* Pre-study relapses indicate the number of relapses during the 2 years prior to the study period; baseline EL, the number of Gd-enhancing lesions on the images obtained at study entry; and on-trial EL, the total number of Gd-enhancing lesions during the 9 months of the study.